ArticleJournal of clinical medicine2021

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study.

Elena Izkhakov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.